← Browse by Condition
Medical Condition

portal hypertension related to cirrhosis

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2

Hypertension remains the most common treatable cardiovascular risk factor globally, yet blood pressure control rates remain suboptimal despite multiple effective drug classes. Clinical trials now investigate novel mechanisms including aldosterone synthase inhibitors, renal denervation devices, and RNA-based therapies targeting angiotensinogen to achieve durable pressure reduction with minimal pill burden.

Active research includes zilebesiran (RNA interference targeting angiotensinogen), baxdrostat (aldosterone synthase inhibitor), ultrasound renal denervation (Symplicity HTN-4), and resistant hypertension approaches combining SGLT2 inhibitors with MRA spironolactone. Ambulatory blood pressure monitoring is increasingly used as the primary endpoint instead of clinic readings.

Frequently Asked Questions — portal hypertension related to cirrhosis Clinical Trials

How many clinical trials are currently recruiting for portal hypertension related to cirrhosis?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for portal hypertension related to cirrhosis, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for portal hypertension related to cirrhosis?
portal hypertension related to cirrhosis research spans Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a portal hypertension related to cirrhosis clinical trial?
Eligibility criteria for portal hypertension related to cirrhosis trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Top Sponsors
University Hospital, Clermont-Ferrand 1 trial
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 1 trial
Assistance Publique - Hôpitaux de Paris 1 trial

Recruiting Clinical Trials

NCT06861075
Recruiting
CARPEUS : Effect of Carvedilol on the Portosystemic Gradient as Measured by Endoscopic Ultrasound
Enrollment
30 pts
Location
France
Sponsor
University Hospital, Clermont-...
View Trial →
NCT07122622
Recruiting
2D-shear Wave Spleen Elastography in Clinically Significant Portal Hypertension and High-risk Varices
Enrollment
450 pts
Location
Italy
Sponsor
Fondazione Policlinico Univers...
View Trial →
NCT06687265 Phase 2
Recruiting
Effects of Metformin on Hepatic Venous Pressure Gradient in Patients With Cirrhosis and Portal Hypertension
Enrollment
76 pts
Location
France
Sponsor
Assistance Publique - Hôpitaux...
View Trial →

Related Conditions

cirrhosis (2) esophageal varices (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology